However, combination therapy with anti-PD-1 or anti-PD-L1 antibodies in HCC models demonstrated far superior anti-tumor efficacy and greater reduction of immunosuppression compared to either agent alone (198). The gene discussed is CD274; the disease is hepatocellular carcinoma.